ProductsClinical ResultsPractitionersVideosHow to BuyCompany News

About Us

History

Incorporated in 1993, Artegraft Inc. offers surgeons a biological alternative to synthetic grafts. Artegraft’s natural collagen matrix has proven long-term patency advantages over ePTFE and other synthetic graft materials. Artegraft is also positioned as an alternative to a non-viable autogenous fistula. Artegraft was the first vascular graft approved by the FDA in 1970 and has been in continuous clinical use for over 45 years. Available in lengths from 15 to 50 cm and in 4, 5, 6, 7 and 8 mm inner diameters, Artegraft is approved for use, distal to the aorta, for segmental bypass, arterial replacement, patch graft, femoropopliteal bypass when the patient’s saphenous is absent or inadequate, but is predominantly used as a hemodialysis graft.

Artegraft is positioned in the market as a biological alternative to synthetic grafts, particularly ePTFE, a thermoplastic that was never designed to be punctured 312 times per year as a hemodialysis graft. Artegraft's natural collagen matrix, as well as its surgical versatility and compliance, has proven long-term patency advantages over ePTFE and other synthetic graft materials. Artegraft is also positioned as an alternative to a non-viable autogenous fistula. Think of it as a Fistula in a Bottle™.

Key Personnel

Clinical Studies

  Frequently Asked Questions Our Manufacturing Process